Otolith Labs Rounds Out Executive Team with Appointment of Kevin Franck, PhD, MBA as Chief Clinical Officer

Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Kevin Franck, PhD, MBA as Chief Clinical Officer. Kevin is a leader in the inner-ear field with 25 years of experience in the development, commercialization, and clinical provision of hearing-related medical products.

As a biotech and medical device executive, Kevin Franck has held numerous leadership roles in the Ear, Nose and Throat (ENT) industry, most recently as SVP, Strategic Marketing and New Product Planning at Frequency Therapeutics, Director of Audiology at Massachusetts Eye and Ear, Faculty of the Department of Otolaryngology-Head and Neck Surgery at Harvard Medical School, and Head of Marketing for Bose Hear at Bose Corporation upon acquisition of Ear Machine, a startup funded by the National Institute of Health. He also held senior roles at Cochlear Ltd. in Sydney, Australia.

Dr. Franck will oversee Otolith's clinical and regulatory strategy. As Otolith prepares for its market launch, Kevin will play a vital role in developing and executing Otolith clinical studies for its submission to the FDA and the go-to-market strategy. After Otolith's market launch, he will expand Otolith's indications for use and products to help millions of people with vestibular disorders.

"We're thrilled Kevin is completing our executive team with his decades of clinical experience. His wealth of knowledge and relationships in the ENT community will be critical in developing partnerships with key opinion leaders and clinicians in the field," said Sam Owen, CEO and Founder of Otolith Labs.

Dr. Franck holds a PhD in Hearing Science from the University of Washington, an MBA in Health Care Management from the Wharton School, an MSE from the Johns Hopkins University in Biomedical Engineering, and a BA in Engineering from Dartmouth College. He is also a licensed and certified audiologist.

"Otolith's breakthrough technology introduces something truly new for clinicians to bring to patients with chronic vertigo, where there is little else to offer. I am excited to join Otolith and help foster much needed innovation in the ENT space," said Dr. Kevin Franck.

For more information on clinical trials or investment inquiries, please email [email protected].

About Otolith Labs

Otolith Labs is developing prescription medical devices for the treatment of vestibular disorders, conditions experienced by millions of Americans. Otolith's patented technology, which received Breakthrough Device Designation from the FDA for the treatment of chronic vertigo, uses precisely tuned vibrations to interact with the acceleration sensors in the inner ear, mitigating the symptoms of vertigo. Otolith is conducting clinical trials to evaluate its technology as an immediate symptom-relief treatment for chronic vertigo associated with vestibular disorders.